Johnson & Johnson Marketed Gynecare ProLift Transvaginal Mesh Device in Defiance of FDA Warning to H

Parker Waichman LLP Reports that FDA Warned Johnson & Johnson to Halt Sales of Gynecare ProLift Transvaginal Mesh Product in August 2007, but the Company Continued Selling Vaginal Implant without FDA Clearance for Nine Months. New York, New York (PRWEB) June 27, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the victims of defective medical devices, is disturbed by a report that Johnson & Johnson continued marketing its Gynecare ProLift transvaginal mesh product for months, in defiance of a Food & Drug Administration (FDA) warning to halt sales of the dev
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories